Ketchum London has clinched an estimated pounds 1.25 million-fee
contract to manage global public relations for Janssen Pharmaceutica’s
schizophrenia drug Risperdal.
The Brussels-based company is believed to be allocating a total budget
in excess of pounds 2 million for Risperdal in order to combat the
imminent launch of schizophrenia treatments from rivals Eli Lilly and
Four directors, including Ketchum’s head of healthcare Paul Blackburn,
an account manager and executive will execute the campaign for
Risperdal, a seratonin and dopa-mine antagonist (SDA).
The team is preparing for its first major event, the World Psychiatric
Association Con-gress, which will be held in Madrid later this month.
Blackburn was cagey about campaign details but said health
professionals, carers and patients will be targeted in the campaign via
trade and consumer media and third party organisations.
Launched in 1993, Risper-dal treats both positive symptoms - delusions
and hallucinations - and negative symptoms such as social withdrawal,
mood change and loss of drive.
According to the mental health charity SANE, one in a hundred people
suffer from schizophrenia symptoms.
Blackburn added that he hoped the new 18-month contract, plus its
appointment to work on Organon’s anti-depressant Remeron last May, would
lift Ketchum into the top 10 healthcare agencies.